Enzo Biochem adjourns the annual meeting of shareholders until

NEW YORK, NY, April 01, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading bioscience and diagnostics company, announced today its 2021 Annual Meeting of Shareholders (“Annual Meeting”), with respect to Proposal 1, has been adjourned until April 8, 2022 at 9:00 a.m. EDT.

The Company has adjourned the annual meeting, held on March 31, 2022, in relation to Proposal 1 in order to allow itself more time to solicit proxies in relation to this proposal. If Proposal 1 is approved, Enzo’s current laddered board structure would be declassified so that all directors are eligible for re-election each year. In addition, votes on the approval of mergers, asset sales and dissolution as well as amendments to Enzo’s certificate of incorporation and articles of association would be subject to majority approval. Further information on Proposition 1 can be found in the company’s definitive proxy statement filed with the United States Securities and Exchange Commission on March 1, 2022,

Proposal 1 of the list of proposals submitted to the annual meeting requires the affirmative vote of holders of at least 80% of the combined voting rights of the outstanding voting shares. The Company has determined that a further adjournment is necessary to allow shareholders who have not yet voted more time to vote. The Annual Meeting will resume virtually via the Internet at www.virtualshareholdermeeting.com/ENZ2022 Friday, April 8, 2022 at 9 a.m. EDT.

The Company encourages all shareholders of record as of February 25, 2022 who have not yet voted on Proposal 1 to vote to approve Proposal 1 by 11:59 p.m. Eastern Daylight Time on April 7, 2022. Registered shareholders may vote for their shares by calling Kingsdale Advisors toll free at 1-888-518-1554 or collect at 1-416-867-2272

The annual meeting has been called for March 31, 2022 with respect to motions 2 (the election of directors), 3 (advisory vote to approve the compensation of our named executive officers) and 4 (ratification of the the Company’s public accountants) each as set forth in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission on March 1, 2022, all of which have been approved. The company filed a current report on Form 8-K with the United States Securities and Exchange Commission on March 31, 2021, disclosing the voting results on these proposals.

About Enzo Biochem


Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that offer many advantages over previous standards. A global company, Enzo Biochem uses cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing healthcare needs of today and tomorrow. Enzo Biochem’s products and technologies are supported by a broad and deep intellectual property portfolio, with patent coverage on a number of key enabling technologies.
For more information, please visit www.Enzo.com or follow Enzo Biochem on Twitter and
LinkedIn.

Forward-looking statements

Except for historical information, the matters discussed in this release may be deemed “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding the intention, belief or current expectations of the Company and its management, including those relating to cash flow, gross margins, revenues and expenses which depend on a number of factors beyond the Company’s control, including, but not limited to, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation and general trade conditions. See the risk factors in the company’s Form 10-K for the fiscal year ended July 31, 2021. Investors are cautioned that these forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. . The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

###
Contact Enzo Biochem

For: Enzo Biochem:

David Banc, Chief Financial Officer
212-583-0100
[email protected]

For the media:

Lynn Granito
Berry & Company Public Relations
212-253-8881
[email protected]

For investors:

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]

Comments are closed.